Abstract：
UNASSIGNED: Tailoring asthma interventions based on biomarkers could substantially impact the high cost associated with asthma morbidity. For policymakers, the main concern is the economic impact of adopting this technology, especially in developing countries. This study evaluates the budget impact of asthma management using sputum eosinophil counts in Colombia patients between 4 and 18 years of age.
UNASSIGNED: A budget impact analysis was performed to evaluate the potential financial impact of sputum eosinophil counts (EO). The study considered a 5-year time horizon and the Colombian National Health System perspective. The incremental budget impact was calculated by subtracting the cost of the new treatment, in which EO is reimbursed, from the cost of the conventional therapy without EO (management based on clinical symptoms (with or without spirometry/peak flow) or asthma guidelines (or both), for asthma-related). Univariate one-way sensitivity analyses were performed.
UNASSIGNED: In the base-case analysis, the 5-year costs associated with EO and no-EO were estimated to be US$ 532.865.915 and US$ 540.765.560, respectively, indicating savings for Colombian National Health equal to US$ 7.899.645, if EO is adopted for the routine management of patients with persistent asthma. This result was robust in univariate sensitivity one-way analysis.
UNASSIGNED: EO was cost-saving in guiding the treatment of patients between 4 and 18 years of age with persistent asthma. Decision-makers in our country can use this evidence to improve clinical practice guidelines, and it should be replicated to validate their results in other middle-income countries.
UNASSIGNED: A budget impact analysis was performed to evaluate the potential financial impact of sputum eosinophil counts (EO). The study considered a 5-year time horizon and the Colombian National Health System perspective. The incremental budget impact was calculated by subtracting the cost of the new treatment, in which EO is reimbursed, from the cost of the conventional therapy without EO (management based on clinical symptoms (with or without spirometry/peak flow) or asthma guidelines (or both), for asthma-related). Univariate one-way sensitivity analyses were performed.
UNASSIGNED: In the base-case analysis, the 5-year costs associated with EO and no-EO were estimated to be US$ 532.865.915 and US$ 540.765.560, respectively, indicating savings for Colombian National Health equal to US$ 7.899.645, if EO is adopted for the routine management of patients with persistent asthma. This result was robust in univariate sensitivity one-way analysis.
UNASSIGNED: EO was cost-saving in guiding the treatment of patients between 4 and 18 years of age with persistent asthma. Decision-makers in our country can use this evidence to improve clinical practice guidelines, and it should be replicated to validate their results in other middle-income countries.
摘要：
背景：基于生物标志物的哮喘干预措施可能会显著影响与哮喘发病率相关的高成本。对于决策者来说，主要关注的是采用这项技术的经济影响，尤其是在发展中国家。这项研究评估了4至18岁哥伦比亚患者使用痰嗜酸性粒细胞计数进行哮喘管理的预算影响。方法：进行预算影响分析以评估痰嗜酸性粒细胞计数（EO）的潜在财务影响。该研究考虑了5年的时间范围和哥伦比亚国家卫生系统的观点。增量预算影响是通过减去新治疗的成本来计算的，其中EO是报销的，从没有EO的常规治疗的费用（基于临床症状的管理（有或没有肺活量测定/峰值流量）或哮喘指南（或两者），与哮喘相关的)。进行单因素单向敏感性分析。结果：在基本案例分析中，与EO和no-EO相关的5年成本估计分别为532.865.915美元和540.765.560美元，表明如果在持续性哮喘患者的常规管理中采用EO，则哥伦比亚国民健康节省等于7.899.645美元。该结果在单变量敏感性单向分析中是稳健的。结论：EO在指导4至18岁持续性哮喘患者的治疗方面可以节省成本。我国的决策者可以利用这些证据来改进临床实践指南，它应该被复制，以验证他们在其他中等收入国家的结果。
